Zobrazeno 1 - 10
of 510
pro vyhledávání: '"E F Smit"'
Autor:
E. A. van de Stadt, M. Yaqub, A. A. Lammertsma, A. J. Poot, P. R. Schober, R. C. Schuit, E. F. Smit, I. Bahce, N. H. Hendrikse
Publikováno v:
EJNMMI Research, Vol 10, Iss 1, Pp 1-9 (2020)
Abstract Introduction Only a subgroup of non-small cell lung cancer (NSCLC) patients benefit from treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as afatinib. Tumour uptake of [18F]afatinib using positron
Externí odkaz:
https://doaj.org/article/ff974949073d42cfa4ad11a0d33b757f
Autor:
M. C. F. Cysouw, S. V. S. Golla, V. Frings, E. F. Smit, O. S. Hoekstra, G. M. Kramer, R. Boellaard, on behalf of the QuIC-ConCePT Consortium
Publikováno v:
EJNMMI Research, Vol 9, Iss 1, Pp 1-11 (2019)
Abstract Background Partial-volume effects generally result in an underestimation of tumor tracer uptake on PET-CT for small lesions, necessitating partial-volume correction (PVC) for accurate quantification. However, investigation of PVC in dynamic
Externí odkaz:
https://doaj.org/article/21b094dc70cc4b5690c3dba78300faca
Autor:
A. N. Niemeijer, D. Leung, M. C. Huisman, I. Bahce, O. S. Hoekstra, G. A. M. S. van Dongen, R. Boellaard, S. Du, W. Hayes, R. Smith, A. D. Windhorst, N. H. Hendrikse, A. Poot, D. J. Vugts, E. Thunnissen, P. Morin, D. Lipovsek, D. J. Donnelly, S. J. Bonacorsi, L. M. Velasquez, T. D. de Gruijl, E. F. Smit, A. J. de Langen
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-5 (2018)
Assessment of PD-1 and PD-L1 expression can be predictive of immunotherapy response in lung cancer. Here the authors assess the clinical toxicity, safety and quality of non-invasive imaging of PD-1 and PD-L1 expression in 13 patients with advanced lu
Externí odkaz:
https://doaj.org/article/d775b429652c43478095f6b7bc6015c1
Autor:
R. Iqbal, G. M. Kramer, V. Frings, E. F. Smit, O. S. Hoekstra, R. Boellaard, on behalf of the QuIC-ConCePT Consortium
Publikováno v:
EJNMMI Research, Vol 8, Iss 1, Pp 1-10 (2018)
Abstract Background 3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT) was proposed as an imaging biomarker for the assessment of in vivo cellular proliferation with positron emission tomography (PET). The current study aimed to validate [18F]FLT as a p
Externí odkaz:
https://doaj.org/article/d383f198c9384799aaa68acbc6f07b82
Autor:
A J van der Wekken, J L Kuiper, A Saber, M M Terpstra, J Wei, T J N Hiltermann, E Thunnissen, D A M Heideman, W Timens, E Schuuring, K Kok, E F Smit, A van den Berg, H J M Groen
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0182885 (2017)
To determine survival in afatinib-treated patients after treatment with first-generation EGFR tyrosine kinase inhibitors (TKIs) and to study resistance mechanisms in afatinib-resistant tumors.Characteristics and survival of patients treated with afat
Externí odkaz:
https://doaj.org/article/93cb6fbdcf78436f94adb5f3693dd368
Autor:
D. Kramer, F. B. Thunnissen, M. I. Gallegos-Ruiz, E. F. Smit, P. E. Postmus, C. J. L. M. Meijer, P.J.F. Snijders, D. A. M. Heideman
Publikováno v:
Cellular Oncology, Vol 31, Iss 3, Pp 161-167 (2009)
Background: Increasing evidence points to a negative correlation between K-ras mutations and patient’s response to, or survival benefit after, treatment with EGFR-inhibitors. Therefore, rapid and reliable assays for mutational analysis of the K-ras
Externí odkaz:
https://doaj.org/article/b3dca800acbe4d7e9877d48b2e718323
Autor:
D. A. M. Heideman, F. B. Thunnissen, M. Doeleman, D. Kramer, H. M. Verheul, E. F. Smit, P. E. Postmus, C. J. L. M. Meijer, G.A. Meijer, P. J. F. Snijders
Publikováno v:
Cellular Oncology, Vol 31, Iss 5, Pp 329-333 (2009)
Background: Increasing data from clinical trials support EGFR and K-ras mutation status as predictive markers of tumour response to EGFR-targeted therapies. Consequently, rapid and reliable mutation screening assays are demanded to guide rational use
Externí odkaz:
https://doaj.org/article/0ea96d7979ce4bb1a0a7eaa416f018b2
Autor:
E A, van de Stadt, M, Yaqub, A A, Lammertsma, A J, Poot, P R, Schober, R C, Schuit, E F, Smit, I, Bahce, N H, Hendrikse
Publikováno v:
EJNMMI Research
Introduction Only a subgroup of non-small cell lung cancer (NSCLC) patients benefit from treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as afatinib. Tumour uptake of [18F]afatinib using positron emission
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::73a86a55f79011a69537a53110ef4fd3
https://pubmed.ncbi.nlm.nih.gov/32804306
https://pubmed.ncbi.nlm.nih.gov/32804306
Autor:
Mingzan, Zhuang, David Vállez, García, Gerbrand M, Kramer, Virginie, Frings, E F, Smit, Rudi, Dierckx, Otto S, Hoekstra, Ronald, Boellaard
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 60(5)
There is increased interest in various new quantitative uptake metrics beyond SUV in oncologic PET/CT studies. The purpose of this study was to investigate the variability and test-retest ratio (TRT) of metabolically active tumor volume (MATV) measur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dbcdf3835f029d234b0f13c2bbbd729b
https://pubmed.ncbi.nlm.nih.gov/30389824
https://pubmed.ncbi.nlm.nih.gov/30389824
Publikováno v:
EJNMMI Research
Background 3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT) was proposed as an imaging biomarker for the assessment of in vivo cellular proliferation with positron emission tomography (PET). The current study aimed to validate [18F]FLT as a perfusion-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::76be4812281e6694e0775d9215d3624d
https://pubmed.ncbi.nlm.nih.gov/29594931
https://pubmed.ncbi.nlm.nih.gov/29594931